Completed PHASE4 INTERVENTIONAL NCT00060866

Propranolol to Treat Fainting Due to Sympathoadrenal Imbalance

Propranolol for Syncope With Sympathoadrenal Imbalance

Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)

Interventions Propranolol

Updated 5 times since 2017 Last updated: Mar 3, 2008 Started: May 31, 2003 Completion: Mar 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00060866, this PHASE4 trial focuses on Neurocardiogenic Syncope and remains completed. Sponsored by National Institute of Neurological Disorders and Stroke (NINDS), it has been updated 5 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

May 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institute of Neurological Disorders and Stroke (NINDS)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States